Navigation Links
Ohr Pharmaceutical Achieves 50% Enrollment Milestone in Squalamine Eye Drop Phase II Clinical Trial
Date:7/10/2013

NEW YORK, July 10, 2013 /PRNewswire/ -- Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has enrolled the first 60 patients in the Company's ongoing OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration ("wet-AMD"). The study is a randomized, double blind, placebo controlled study enrolling patients at more than twenty clinical sites in the U.S.

"We are excited to have reached the halfway point in the enrollment of our Squalamine Eye Drop study," said Dr. Irach B. Taraporewala, CEO of Ohr. "This milestone sets the stage for the planned interim analysis once the 60 patients complete the nine month treatment protocol, and we expect the data to be available in the second quarter of 2014."

"I am pleased with the continued progress in the trial to evaluate Squalamine Eye Drops for exudative AMD," commented Dr. Jason Slakter, retinal disease specialist at Vitreous-Retina-Macula Consultants of NY, and member of Ohr's scientific advisory board. "The Company's eye drop for treating wet-AMD would potentially offer patients a convenient, self-administered, treatment alternative or adjunct to currently used intravitreal injections directly into the eye. This could be a significant advancement in the future treatment of wet-AMD."

Study OHR-002 is a randomized, double blind, placebo controlled Phase II study to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of wet-AMD. The study will enroll 120 treatment naive wet-AMD patients at more than twenty clinical sites in the U.S., who will be treated with Squalamine Eye Drops or placebo eye drops twice daily for a nine month period. The primary and secondary endpoints include visual acuity parameters, need for rescue intravitreal inj
'/>"/>

SOURCE Ohr Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... (PRWEB) December 25, 2014 The report ... by Product Type & Provider Type - Global Advancements, ... market with an in-depth analysis and forecasting of revenues. ... spread through 221 pages and in-depth TOC on “Service ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, ... announced the closing of an underwritten public offering of 3,500,000 ... an aggregate 3,500,000 shares of common stock, at an offering ... warrants have a per share exercise price of $5.00, are ...
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   BioLife Solutions ... manufacturer and marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" or ... Annual Meeting of Stockholders on May 4, 2015 (the "Annual ...
(Date:12/24/2014)... GMO corn cases filed across the United States, and ... being consolidated in a Kansas federal court for pretrial proceedings. ... Corn Litigation, MDL No. 2591 in the U.S. District Court ... GMO corn multidistrict litigation (MDL) has been handed over to ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... S and CHT , Ceramic ... Henry Lai, PhD, and Samuel G Franklin, PhD, Bio-Rad Laboratories, Inc., , ... , Introduction , ... , using the conventional process composed of a protein ...
... , , ... isolates RNA or cDNA from in vitro ... antisense RNA amplification reactions. As gene expression profiling , ... , effective, automated purification reagent is required. ...
... RNAPrep is a SPRI based magnetic bead purification ... from, Eukaryotic cultured cells. RNAPrep is a simple ... RNA for use in applications such as microarray , ... format is scalable and consistently delivers high yield recovery and purity , ...
Cached Biology Technology:Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 2Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 3Purification of Murine IgG1 Using UNOsphere S and CHT , Ceramic Hydroxyapatite Chromatography, Rev A 4RNA & cDNA Purification Using RNAClean 2RNA & cDNA Purification Using RNAClean 3RNA & cDNA Purification Using RNAClean 4RNA & cDNA Purification Using RNAClean 5RNAPrep - Total RNA Isolation Purification 2RNAPrep - Total RNA Isolation Purification 3
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in India ... One major trend emerging in this market is the ... more than one characteristic of an individual for verification ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced plans ... Medicine. Funding for this $50 million capital project is part ... next summer. The medical education building will ... Company complex, adjacent to 525@vine in Wake Forest Innovation Quarter. ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Climate-KIC, Europe,s largest public-private innovation partnership working to address ... to FuME (Fugitive Methane Emissions), a new project that ... methane emissions are of great importance to climate change ... its high global warming impact . Capturing fugitive methane ...
... cellular heaven and hell, a crane fly sperm cell undergoing ... recognized with the top three awards in the American Society ... for 2013. The awards were announced and the ... , Dec. 14, in New Orleans. The Celldance Awards Ceremony ...
... Reindeer, from Northern Europe or Asia, are often thought of ... Caribou, similar in appearance but living in the wilderness of ... adventurous life. However, new research published in the journal ... about these two animals than previously thought and change in ...
Cached Biology News:Tailored methane measurement services are to be developed for shale gas extraction, municipal waste 2Tailored methane measurement services are to be developed for shale gas extraction, municipal waste 3Celldance 2013 video awards, the 'Cell Oscars,' roll out tiny red carpet 2Celldance 2013 video awards, the 'Cell Oscars,' roll out tiny red carpet 3Climate change will endanger caribou habitat, study says 2
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... MULTI-FUN Incubator is a compact ... uses a microprocessor controller with a ... temperature and agitation speed. Air circulation ... the incubator. Temperature can be easily ...
... Nonanoyl-N-methylglucamide White solid. ... be readily removed by dialysis. Useful ... ≥98% by HPLC. Absorbance (10%, ... 2 O. CMC 19 - 25 ...
Biology Products: